IDR - Immune Diagnostics & Research

Original Articles

Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection


Natasa Popovic, Milos Korac, Zorica Nesic, Branko Milosevic, Aleksandar Urosevic, Djordje Jevtovic, Mijomir Pelemis, Dragan Delic, Milica Prostran, Ivana Milosevic

Clinic for Infectious and Tropical Diseases, Clinical Centre Serbia, Belgrade, Serbia

doi:10.3855/jidc.6335

Abstract

Introduction: Clostridium difficile is the leading cause of hospital-acquired diarrhoea. There is no defined protocol for treating severe Clostridium difficile infection (CDI) refractory to vancomycin or vancomycin and metronidazole combination therapy. The aim of this study was to evaluate the rate of clinical cure, time to resolution of diarrhoea and recurrence rate in patients with severe refractory CDI treated with oral teicoplanin.

Methodology: A one-year prospective study was carried out in the Clinic for Infectious and Tropical Diseases, Clinical Center Serbia. Patients with severe and complicated CDI who failed to respond to oral vancomycin and intravenous metronidazole combination therapy were enrolled. They were given oral teicoplanin 100 mg bi-daily. Patients were followed for recurrence for eight weeks.

Results: Nine patients with a mean age of 70.8±9.4 years were analyzed. All patients had pseudomembranous colitis, and five had complicated disease. In four patients intracolonic delivery of vancomycin was also performed in addition to oral vancomycin and intravenous metronidazole prior to initiating teicoplanin, but without improvement. After teicoplanin initiation all patients achieved clinical cure. The mean time to resolution of diarrhoea after teicoplanin introduction was 6.3±4.5 days. There was no statistically significant difference in time to resolution of diarrhoea according to initial leucocyte count, age over 65 years, the presence of ileus, complicated disease and the use of concomitant antibiotic therapy (p = 0.652, 0,652, 0.374, 0.374, and 0,548, respectively). None of the patients experienced recurrence.

Conclusions: Oral teicoplanin might be a potential treatment for severe and complicated refractory CDI, but further studies are required.


Keywords

oral teicoplanin; Clostridium difficile; refractory pseudomembranous colitis; recurrence

Full Text:

PDF